Vall d'Hebron Institute of Oncology (VHIO)
Javier Carmona Sanz is a prominent scientific leader currently serving as Chief Scientific Officer at Cancer Core Europe and Head of Scientific Strategy and Translational Programs at Vall d'Hebron Institute of Oncology. Additionally, Javier holds positions as a Visiting Professor in Science Management at Universitat Autònoma de Barcelona and in Science Communication at the University of Navarra. Javier's previous roles include Consulting Editor for npj Precision Oncology and various editorial positions at Nature Medicine, along with freelance editorial and writing work that focuses on translating complex scientific concepts for broader audiences. Javier's academic background includes a Bachelor of Science in Cellular and Molecular Biology from Universidad Autónoma de Madrid and a Diploma in Biology from the University of Navarra, complemented by postdoctoral research at Memorial Sloan-Kettering Cancer Center and a PhD at IDIBELL.
This person is not in any teams
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.